Emcure Pharmaceuticals Ltd

  • BSE Code : 544210
  • NSE Symbol : EMCURE
  • ISIN : INE168P01015
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN

up-arrow 1,547.60 -42.50(-2.67%)

Open Price ()

1,585.50

Prev. Close ()

1,590.10

Volume (No’s)

414,990

Market Cap ()

29,340.88

Low Price ()

1,457.00

High Price ()

1,585.50

 

Board Meetings

Start Date End Date Purpose
09-Mar-2026 09-Mar-2026 Outcome of Board Meeting held on March 09, 2026
22-Jan-2026 04-Feb-2026 Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve Board Meeting intimation for approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025 Outcome of Board Meeting held on February 04, 2026. (As per BSE Announcement dated on: 04.02.2026)
03-Nov-2025 11-Nov-2025 Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and half-year ended September 30 2025 Unaudited Financial Results (Consolidated and Standalone) for the quarter and half-year ended September 30, 2025 (As per BSE Announcement dated on: 11.11.2025)
28-Jul-2025 07-Aug-2025 Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter ended June 30 2025. Outcome of Board Meeting held on August 07, 2025 to approve the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025 (As per BSE Announcement Dated on 07/08/2025)
21-Jun-2025 21-Jun-2025 Outcome of Board Meeting held on June 21, 2025 Acquisition of Equity Shares, constituting 20.42% of the total issued and paid-up capital of Zuventus Healthcare Limited, a subsidiary of the Company, thereby making Zuventus a wholly-owned subsidiary of the Company. Intimation under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of the meeting of the Board of Directors considering requests for re-classification from the 'Promoter and Promoter Group'' category to ''Public'' category

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew